The Medicare agency is proposing changes, including ending “burdensome” data requirements, for implantable heart devices for the first time in over a dozen years.
The Centers for Medicare & Medicaid Services announced last week it was seeking to update coverage decisions for implantable cardioverter defibrillators (ICDs), including eliminating some waiting periods and requiring patient-doctor decision making for some patients. The proposal would be the only major update to Medicare’s ICD coverage since 2005, and hospitals and device groups say an update is long overdue.
ICDs are battery-powered devices that treat abnormally fast, life-threatening heart rhythms by delivering a shock to the heart, restoring the heart’s normal rhythm and preventing cardiac arrest. The devices come with a heavy price tag, costing an average of $30,000 per device according to Medtronic. In order to receive Medicare reimbursement for ICDs, providers currently must submit data sets to the CMS that provide more information about the safety and effectiveness of the device.
The coverage determination data requests were intended to ascertain whether ICDs were safe and necessary enough to perform in clinical settings. Industry groups and hospitals have said the evidence and data the CMS has collected for the past 12 years have supported clinical use of ICDs.
Chandra Branham, vice president of payment and health-care delivery policy at the Advanced Medical Technology Association, told Bloomberg Law the group is still reviewing the proposal but upon first glance it supports the removal of the data collection requirement.
Read my full article here.
Stay on top of new developments in health law and regulation, and learn more, by signing up for a free trial to Bloomberg Law.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)